引入针对多重耐药菌的新抗生素:障碍与前进之路
该综述检索了2013至2023年间针对多重耐药菌新抗生素的3期随机对照试验、指南及获取、使用、监管和抗菌药物管理相关文献,指出新抗生素获批时证据存在多项缺口,现行指南可能增加新抗生素使用并加速耐药发展,且抗生素可及性存在严重不平等,欧洲各国的获取策略与抗菌药物管理努力不够平衡。
要点
- 新抗生素获批时在试验目标人群、对照选择、非劣效假设和耐药发展评估等方面存在证据缺口。
- 现行指南可能增加新抗生素使用,从而加速耐药发展。
- 抗生素可及性图谱显示新抗生素获取存在严重不平等,欧洲各国获取策略与抗菌药物管理不够平衡。
核心结论
- 抗生素耐药是紧迫威胁,本综述强调需要在各国和地理区域间采取更系统和统一的策略,以改善新广谱抗生素的证据、可及性和使用。
研究设计与样本
- 综述检索PubMed中2013至2023年间关于多重耐药菌新抗生素的3期随机对照试验、指南及获取、使用、监管和抗菌药物管理相关文献。
- 其他来源包括关于新抗生素报销和使用政策的政府和专业文件。
主要发现
- 新抗生素的证据缺口涉及试验目标人群、对照选择、试验内管理算法、非劣效假设和研究中的耐药发展评估。
- 现行指南存在增加新抗生素使用并因此加速耐药发展的风险。
- 更新的抗生素可及性图谱显示新抗生素获取存在严重不平等。
- 欧洲各国用于提供新抗生素可及性的策略未被抗菌药物管理努力充分平衡,以校准新抗生素的审慎使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following intense efforts to revive the dry antibiotic research and development pipeline, a few highly awaited antibiotics with activity against multidrug-resistant (MDR) bacteria were recently approved. OBJECTIVES: We aim to highlight gaps in the evidence generated for new antibiotics by the time of their approval and to review the consequent limitations of treatment guidelines for priority MDR bacteria. We also report on the availability of the new antibiotics, reimbursement strategies allowing the use of these antibiotics in hospitals, and antibiotic stewardship efforts. SOURCES: We searched PubMed for phase 3 randomized controlled trials, guidelines, and publications on access, usage, regulatory aspects and antimicrobial stewardship of antibiotics approved for use against MDR bacteria between 2013 and 2023. Other sources included governmental and professional documents regarding policies for reimbursement and use of the new antibiotics. CONTENT: Several gaps in the evidence available regarding the new antibiotics are described related to the trials' target populations, comparators, management algorithm within the trial, non-inferiority hypotheses, and assessment of resistance development within the studies. We highlight the risk of current guidelines to increase the usage of new antibiotics and consequently accelerate resistance development. Updated mapping of antibiotic availability reveals critical inequality in access to the new antibiotics. Finally, strategies used nationally in Europe to provide access to the new antibiotics are not sufficiently balanced by antibiotic stewardship efforts to calibrate the judicious use of the new antibiotics. IMPLICATIONS: Antibiotic resistance is an immediate threat. The present review highlights areas where more systematic and uniform strategies across countries and geographical regions are warranted to improve evidence, availability, and use of new broad-spectrum antibiotics.
引用
- Tängdén T, Carrara E, Hellou MM, et al. Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward. Clin Microbiol Infect. 2024. PMID: 39374649. doi:10.1016/j.cmi.2024.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。